4.8 • 1K Ratings
🗓️ 31 January 2024
⏱️ 25 minutes
🧾️ Download transcript
How do you counsel patients eligible for the RSV vaccines? What do the results of the RENOIR and AReSVi trials tell us and how do they compare? How should we interpret vaccine trials in the first place? Tune in to the fourth episode of Beyond Journal Club, a new series brought to you by Core IM in collaboration with NEJM Group.
Sponsor: Pathway FREE evidence-based clinical decision support app. Guideline summaries, interactive algorithms, landmark trials & more
Tags: IMCore, CoreIM, primary care, infectious disease, nurse practitioner, pharmacist, physician assistant
Click on a timestamp to play from that location
0:00.0 | Welcome to the fourth installment of Beyond Journal Club, a collaboration between CoreM and NHAM group. |
0:05.6 | The goal of Beyond Journal Club is to take landmark clinical trials and put them into context, |
0:10.9 | telling the story of how we got to where we are and what it means for how we take care of patients. |
0:16.0 | And today, we're discussing a topic that somehow become politically charged over the last couple of years. |
0:20.0 | We're talking vaccines and vaccination. I'm Dr. Anne Chung, an editorial fellow at the New England Journal of Medicine and a pediatric hospitalist at Tufts Medical Center with a background of vaccine development. |
0:31.0 | I'm Dr. Greg Katz, a cardiologist at NYU. And I'm Dr. |
0:34.7 | Clemley, a former fellow and current guest editor at the New England Journal of Medicine. |
0:38.4 | Today we're going to talk about the Renraur and RSV trials, which were published in the February 22nd and April 5th |
0:44.3 | issues of the New England Journal Medicine in 2023. These trials were the ones that |
0:49.2 | led to the FDA's approval of G.S. K.'s RXV. and Pfizer's Abrizbo vaccines, the 2023-24 respiratory season. |
0:57.0 | And just to make it clear, yes, you heard that right. |
1:00.0 | One of the RSV trials is called R-S-V spelled A-R-E-S-V-I and the virus is obviously also called |
1:08.5 | R-S-M-V. So that's a pretty convenient way to name the trial after the virus but it's not so |
1:16.6 | convenient when you're doing a podcast talking about both of them. |
1:19.3 | So nomenclature aside I'm getting tons of questions for my patients about these new RSV vaccines as they're |
1:24.8 | bombarded with direct-to-consumer advertising and tons of media coverage and somehow a lot of |
1:29.8 | my patients are a little bit vaccine hesitant and so there's plenty of questions about |
1:33.4 | side effects and efficacy. Yeah I've noticed that too Greg. Vaccines have become a |
1:37.6 | bigger issue for all of our patients since the pandemic and it's not just the |
1:41.4 | R. S. Ers. V. vaccine. So interpreting trials like the RSV trial and the Renoir trial |
1:46.0 | bring up bigger questions about vaccine trials in general. |
1:49.0 | Questions like how do we evaluate the efficacy |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Core IM Team, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Core IM Team and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.